Free tool
FAERS Monitor: Epaned
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 208686 or its brand name (Epaned, Enalapril Maleate). Reports on generic versions are filed under their own applications.
Reports
19,244
Serious
16,050
83% of reports
Hospitalization
9,474
Death reported
2,248
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- diarrhoea1,002
- nausea989
- dyspnoea960
- fatigue849
- dizziness812
- drug interaction797
- drug ineffective730
- vomiting719
- asthenia660
- pain649
- headache637
- hypertension637
- fall631
- renal failure acute621
- hypotension615
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 933 |
| 2005 | 931 |
| 2006 | 1,119 |
| 2007 | 1,006 |
| 2008 | 1,475 |
| 2009 | 1,201 |
| 2010 | 1,597 |
| 2011 | 2,111 |
| 2012 | 1,671 |
| 2013 | 373 |
| 2014 | 458 |
| 2015 | 478 |
| 2016 | 532 |
| 2017 | 552 |
| 2018 | 654 |
| 2019 | 632 |
| 2020 | 578 |
| 2021 | 581 |
| 2022 | 559 |
| 2023 | 548 |
| 2024 | 527 |
| 2025 | 423 |
| 2026 | 304 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,034,915 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| renal failure acuteSignal | 621 | 16.2 | 15.0 | 8,743 |
| drug interactionSignal | 797 | 5.5 | 5.2 | 2,948 |
| hypotensionSignal | 615 | 3.4 | 3.1 | 1,023 |
| hypertensionSignal | 637 | 3.3 | 3.1 | 1,023 |
| fallSignal | 631 | 2.1 | 1.9 | 355 |
| asthenia | 660 | 1.9 | 1.8 | 295 |
| dyspnoea | 960 | 1.9 | 1.7 | 387 |
| dizziness | 812 | 1.8 | 1.7 | 283 |
| diarrhoea | 1,002 | 1.7 | 1.6 | 295 |
| vomiting | 719 | 1.7 | 1.6 | 198 |
| nausea | 989 | 1.4 | 1.3 | 100 |
| fatigue | 849 | 1.2 | 1.1 | 27 |
| pain | 649 | 1.2 | 1.1 | 14 |
| headache | 637 | 1.1 | 1.0 | 7 |
| drug ineffective | 730 | 0.6 | 0.6 | 200 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.